SCHEDULE: AQR Capital Management Discloses Aldeyra Therapeutics Stake

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed a Schedule 13G, reporting beneficial ownership of 6.22% of Aldeyra Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have filed a Schedule 13G, indicating their beneficial ownership of Aldeyra Therapeutics, Inc. common stock.
• As of June 30, 2026, the reporting entities collectively beneficially owned 3,751,558 shares, representing 6.22% of the class of securities.
• This filing is made under Rule 13d-1(b), classifying AQR Capital Management, LLC as an investment adviser.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake without new strategic information or significant changes in holdings.

Positives

• AQR Capital Management, a significant investment management firm, has taken a notable stake in Aldeyra Therapeutics, potentially signaling confidence in the company's long-term prospects.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Negatives

• The filing does not provide any new strategic insights or indicate any active engagement by AQR Capital Management in the company's operations.
• The passive nature of the ownership reported in this Schedule 13G suggests no immediate catalyst for significant stock price movement based on this filing alone.

Risks

• As a Schedule 13G filing, it represents passive investment, meaning AQR Capital Management is not actively seeking to influence or control Aldeyra Therapeutics, thus offering limited insight into strategic direction.
• The filing does not detail the specific investment strategy or the rationale behind acquiring this stake, leaving potential investors to speculate on AQR's outlook for Aldeyra.

Future Outlook

The filing itself does not contain forward-looking statements or specific guidance from Aldeyra Therapeutics. It solely reports on the ownership stake of AQR Capital Management.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by a large asset manager like AQR Capital Management is common and typically indicates a passive investment. It does not, in itself, signal a change in Aldeyra Therapeutics' strategic direction or operational performance, but rather reflects AQR's portfolio management activities.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's passive stake, which may be viewed positively by some, but it does not provide immediate catalysts for price change.
• Management of Aldeyra Therapeutics: The passive nature of the investment suggests no immediate pressure or influence from AQR Capital Management on corporate strategy or governance.
• Potential Investors: The filing provides information on ownership but lacks details on AQR's investment thesis, requiring further due diligence.

Next Steps

• AQR Capital Management will continue to hold its shares in Aldeyra Therapeutics in the ordinary course of business.
• Further filings will be made if AQR Capital Management's beneficial ownership changes significantly.

Key Dates

Keywords

Aldeyra Therapeutics, AQR Capital Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, Shareholder